Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cholestatic Liver Disease Clear all

Conditions: Alagille Syndrome, Cholestasis, Biliary Atresia
Interventions: magnesium gluconate, magnesium sulfate; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 3 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Hepatic Pruritus, Cholestatic Liver Disease, Primary Biliary Cholangitis, Cholestasis, Primary Sclerosing Cholangitis
Interventions: Nemolizumab-ilto; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Alagille Syndrome
Interventions: LUM001, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cholestasis, Red Cell Membrane and Enzyme Abnormalities
Interventions: ektacytometry of red blood cells; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Biliary Cirrhosis
Interventions: Genetic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alagille Syndrome
Interventions: LUM001 (Maralixibat); Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Interventions: Not listed
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Phoenix, Arizona • Aurora, Colorado • St Louis, Missouri + 1 more

Conditions: Pruritus, Liver Cirrhosis, Biliary, Hepatitis C
Interventions: sertraline; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 21 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)
Interventions: LUM001 (Maralixibat); Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 12 Months to 18 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Cincinnati, Ohio + 2 more

Conditions: Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions: Maralixibat, Placebo; Drug · Other
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more

Conditions: Drug Induced Liver Injury
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 2 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 3 more

Conditions: Liver Diseases
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 2 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 3 more

Conditions: Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
Interventions: Maralixibat; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 0 Days to 364 Days
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Genetic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 5 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 9,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2050
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cholestasis
Interventions: Linerixibat; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: Davis, California • West Hollywood, California • Miami, Florida + 8 more

Conditions: Primary Sclerosing Cholangitis
Interventions: ursodeoxycholic acid (UDCA); Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 5 Years to 21 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Liver Diseases, Alagille Syndrome, Alpha 1-Antitrypsin Deficiency
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 25 Years
Enrollment: 1,675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension, Liver Fibrosis, Cholestasis
Interventions: Liver Stiffness Measurement (LSM); Other
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 21 Years
Enrollment: 552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Hepatic Impairment
Interventions: Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • San Antonio, Texas

Conditions: Cholestatic Pruritus
Interventions: CR845 1.0 mg, Placebo; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Coronado, California • Rialto, California • San Francisco, California + 10 more

Conditions: Pruritus
Interventions: EP547, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more

Search by objective public record fields.

Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease

Treatment of Cholestatic Pruritus With Sertraline

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

Drug-Induced Liver Injury (DILI) Network Retrospective

DILIN - Prospective Study

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Genomics of Primary Sclerosing Cholangitis (PSC)

Biobank for Cholestatic Liver Diseases.

Linerixibat Long-term Safety, and Tolerability Study

Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)

FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)

Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis